Should a middle‑aged man with essential hypertension, type 2 diabetes mellitus, acute left‑side weakness (NIHSS 4) and MRI‑confirmed acute right ischemic stroke without large‑vessel occlusion be treated with intravenous alteplase (tPA)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Do Not Administer IV Alteplase – This Patient's Deficits Have Resolved

This patient should receive aspirin and clopidogrel (dual antiplatelet therapy), not IV alteplase, because by the time imaging was completed, he had complete resolution of neurologic deficits (NIHSS effectively 0). This represents a "stroke mimic" or transient ischemic attack with complete resolution, which is a contraindication to thrombolytic therapy.

Critical Clinical Context

The case describes a wake-up stroke with initial NIHSS of 4 (left-sided weakness, pronator drift), but crucially states: "on repeat examination after imaging is completed, no neurologic deficits observed." This complete resolution of symptoms fundamentally changes the risk-benefit calculation for thrombolysis.

Why IV Alteplase is NOT Indicated

Resolved Deficits = Contraindication

  • The 2018 AHA/ASA guidelines 11 clearly state that IV alteplase is indicated for patients with acute stroke symptoms within the treatment window
  • When deficits completely resolve before treatment can be administered, the patient no longer meets criteria for thrombolysis
  • The risk of symptomatic intracranial hemorrhage (2-6%) cannot be justified when there are no persistent neurologic deficits to improve

Wake-Up Stroke Considerations

  • While this patient has a wake-up stroke (last known well >4.5 hours), the MRI showing acute infarct without large vessel occlusion would typically make him eligible for thrombolysis 11
  • However, this eligibility is negated by the complete resolution of symptoms before treatment

Risk-Benefit Analysis

  • Alteplase carries a 2.3-6% risk of symptomatic hemorrhage 2
  • With NIHSS now 0, there is no neurologic deficit to improve
  • The potential harm significantly outweighs any theoretical benefit

Recommended Management: Dual Antiplatelet Therapy

Aspirin plus clopidogrel (option #1) is the appropriate choice for this patient with:

  • Confirmed acute ischemic stroke on MRI (right precentral infarct)
  • No large vessel occlusion
  • Complete resolution of symptoms (high-risk TIA equivalent)
  • Already on aspirin monotherapy

Supporting Evidence

  • The 2018 guidelines 1 recommend IV alteplase for patients taking antiplatelet monotherapy or combination therapy when they have persistent stroke symptoms
  • For high-risk TIA or minor stroke with rapid improvement, dual antiplatelet therapy is the standard of care
  • This patient's diabetes and hypertension increase recurrent stroke risk, supporting aggressive antiplatelet therapy 3

Why Other Options Are Incorrect

IV Labetalol (#3)

  • Blood pressure is 194/93 mmHg
  • BP lowering is only indicated to <185/110 if giving alteplase 1
  • Since alteplase is contraindicated, aggressive BP lowering is not needed acutely
  • Permissive hypertension is appropriate in acute stroke without thrombolysis

IV Heparin (#4)

  • No role in acute ischemic stroke without large vessel occlusion
  • Not indicated for completed stroke with small vessel disease
  • Increases bleeding risk without proven benefit

Clinical Pitfalls to Avoid

  1. Don't treat imaging alone – The MRI shows acute infarct, but clinical examination drives treatment decisions
  2. Reassess before treatment – Always perform a repeat neurologic exam immediately before administering thrombolytics
  3. Document timing carefully – Note when deficits resolved relative to imaging and potential treatment time
  4. Consider the natural history – Patients with spontaneous early improvement have better prognosis and different risk-benefit profiles

Practical Algorithm

For patients with initial stroke symptoms but resolved deficits:

  1. Confirm complete resolution with detailed neurologic exam
  2. Document NIHSS = 0 or return to baseline
  3. Do not administer thrombolytics
  4. Initiate dual antiplatelet therapy (aspirin + clopidogrel)
  5. Pursue aggressive secondary prevention
  6. Admit for observation and stroke workup

The evidence consistently shows that thrombolysis benefits patients with persistent neurologic deficits 113. When symptoms resolve completely, as in this case, the treatment paradigm shifts to antiplatelet therapy and secondary prevention rather than acute reperfusion therapy.

References

Related Questions

In a diabetic patient presenting with acute ischemic stroke, should alteplase be administered and what glucose management is recommended?
What should be done if neuroimaging is negative but the clinical picture is classic for an acute stroke?
How should a 10-year-old child presenting with cough and wheeze be evaluated and managed?
How should I evaluate and manage a patient with a blood pressure of 122/77 mm Hg and a heart rate of 123 beats per minute (tachycardia)?
How should I manage vomiting in an 11-month-old infant?
What are the recommended medication treatment options for anxiety?
What beta‑blocker is appropriate for treating tachycardia in a patient with hyperthyroidism who also has asthma?
In a 27‑year‑old male with borderline‑elevated glycated hemoglobin (HbA1c) and mildly elevated fasting glucose, not on insulin or oral hypoglycemic agents, and presenting with three weeks of vomiting, loss of appetite, and emaciation, should a C‑peptide level be obtained to assess his condition?
In a 67-year-old woman with a three-month history of watery diarrhea, negative stool studies, and improvement while on antibiotics, which dietary intervention should be tried?
What is the appropriate rituximab dosing schedule, premedication, monitoring, and safety considerations for a patient with follicular lymphoma?
How does increased investment in substance‑use‑disorder treatment reduce healthcare expenses related to emergency department visits and hospitalizations for acute and chronic medical conditions?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.